MIGNONE ROBERTO
SEC CIK 1258394 · EDGAR
BoughtSold
Most active insiders at GH, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Talasaz AmirAli | Co-CEO, Dir | — | $84.25M |
| 2 | Eltoukhy Helmy | Co-CEO, Dir | — | $22.03M |
| 3 | Freeman Chris | Chief Commercial Off | — | $16.92M |
| 4 | Monroe Terilyn J. | CHRO | — | $15.95M |
| 5 | Bell Michael Brian | CFO | — | $8.81M |
| 6 | CLARK IAN T | Dir | — | $6.06M |
| 7 | Kalia Kumud | CIO | $78.5K | $5.91M |
| 8 | Chudova Darya | CTO | — | $4.36M |
| 9 | Saia John G. | CLO | — | $4.25M |
| 10 | Krognes Steve E. | Dir | — | $2.40M |
| 18 | MIGNONE ROBERTO | Dir | — | — |
Transactions 23
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-09-22 16:33 | 2026-09-21 | GH | Guardant Health, Inc. | MIGNONE ROBERTO | Dir | M - OptEx | $0.00 | +264 | 10.3K | +3% | $0 |
| I | 2026-09-22 16:21 | 2026-09-18 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | MIGNONE ROBERTO | Dir | S - Sale | $39.06 | -367.6K | 0 | -100% | -$14.36M |
| D | 2026-08-24 17:20 | 2026-08-21 | GH | Guardant Health, Inc. | MIGNONE ROBERTO | Dir | M - OptEx | $0.00 | +264 | 10.0K | +3% | $0 |
| D | 2026-07-22 17:15 | 2026-07-21 | GH | Guardant Health, Inc. | MIGNONE ROBERTO | Dir | M - OptEx | $0.00 | +264 | 9,746 | +3% | $0 |
| DM | 2026-06-23 17:28 | 2026-05-21+ | GH | Guardant Health, Inc. | MIGNONE ROBERTO | Dir | M - OptEx | $0.00 | +528 | 9,482 | +6% | $0 |
| D | 2026-06-22 17:54 | 2026-06-17 | GH | Guardant Health, Inc. | MIGNONE ROBERTO | Dir | M - OptEx | $0.00 | +4,203 | 8,954 | +88% | $0 |
| D | 2026-06-08 16:02 | 2026-06-05 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | MIGNONE ROBERTO | Dir | M - OptEx | — | +14.5K | 119.8K | +14% | — |
| D | 2026-04-22 18:17 | 2026-04-21 | GH | Guardant Health, Inc. | MIGNONE ROBERTO | Dir | M - OptEx | $0.00 | +264 | 4,751 | +6% | $0 |
| D | 2026-03-23 | 2026-03-21 | GH | Guardant Health, Inc. | MIGNONE ROBERTO | Dir | M - OptEx | $0.00 | +264 | 4,487 | +6% | $0 |
| D | 2026-02-23 | 2026-02-21 | GH | Guardant Health, Inc. | MIGNONE ROBERTO | Dir | M - OptEx | $0.00 | +264 | 4,223 | +7% | $0 |
| D | 2026-01-22 | 2026-01-21 | GH | Guardant Health, Inc. | MIGNONE ROBERTO | Dir | M - OptEx | $0.00 | +264 | 3,959 | +7% | $0 |
| D | 2025-12-23 | 2025-12-21 | GH | Guardant Health, Inc. | MIGNONE ROBERTO | Dir | M - OptEx | $0.00 | +264 | 3,695 | +8% | $0 |
| I | 2025-12-18 | 2025-12-16 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | MIGNONE ROBERTO | Dir | S - Sale | $30.24 | -77.4K | 367.6K | -17% | -$2.34M |
| I | 2025-12-01 | 2025-11-26 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | MIGNONE ROBERTO | Dir | S - Sale | $26.03 | -50.0K | 445.0K | -10% | -$1.30M |
| D | 2025-11-24 | 2025-11-21 | GH | Guardant Health, Inc. | MIGNONE ROBERTO | Dir | M - OptEx | $0.00 | +264 | 3,431 | +8% | $0 |
| I | 2025-11-10 | 2025-11-06 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | MIGNONE ROBERTO | Dir | S - Sale | $24.11 | -200.0K | 495.0K | -29% | -$4.82M |
| D | 2025-10-22 | 2025-10-21 | GH | Guardant Health, Inc. | MIGNONE ROBERTO | Dir | M - OptEx | $0.00 | +3,167 | 3,167 | New | $0 |
| D | 2025-06-09 | 2025-06-06 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | MIGNONE ROBERTO | Dir | M - OptEx | — | +9,632 | 105.3K | +10% | — |
| I | 2024-12-26 | 2024-12-20 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | MIGNONE ROBERTO | Dir | S - Sale | $22.01 | -286.0K | 695.0K | -29% | -$6.29M |
| I | 2024-06-21 | 2024-06-18 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | MIGNONE ROBERTO | Dir | S - Sale | $17.03 | -519.0K | 981.0K | -35% | -$8.84M |
| D | 2024-06-17 | 2024-06-15 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | MIGNONE ROBERTO | Dir | M - OptEx | — | +21.1K | 1.60M | +1% | — |
| D | 2023-08-07 | 2023-08-04 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | MIGNONE ROBERTO | Dir | M - OptEx | — | +15.8K | 1.57M | +1% | — |
| D | 2022-06-16 | 2022-06-14 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | MIGNONE ROBERTO | Dir | M - OptEx | — | +14.5K | 58.8K | +33% | — |
Purchase Sale Sale after option exercise All abbreviations